Loading data for SLDB — first visit, this takes a few seconds.

알림

Solid Biosciences Inc. (SLDB)

NasdaqGS: SLDB · 실시간 가격 · USD

9.70

+0.62 (6.83%)

종가 기준: Aug 18, 2026, 3:59 PM

6.83% (1D)

매수호가	7.03
시가총액	1.04B
매출 (ttm)	n/a
순이익 (ttm)	-207.1M
베타	2.42
EPS (ttm)	-1.89
P/E (ttm)	n/a
선행 P/E	-5.54
P/B (ttm)	2.72
P/S (ttm)	n/a
Earnings Date	Nov 2, 2026

매도호가	12.01
거래량	264,557
평균 거래량 (20일)	1,613,285
시가	9.42
전일 종가	9.08
일중 범위	9.29 - 9.87
52주 범위	3.79 - 11.45
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

SLDB 소개

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the trea...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jan 26, 2018

직원 수 121

상장 거래소 NasdaqGS

티커 SLDB

웹사이트 https://www.solidbio.com

전체 기업 정보

재무 실적

2025년 Solid Biosciences의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -174.32M로, 39.8% 증가했습니다.

재무제표

어닝 서프라이즈

Solid Biosciences가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.38 예상치 상회 0.09, 및 35.59% 전년 대비 성장.

다음 실적 발표

Solid Biosciences Inc.의 실적 발표 예정일은 Nov 2, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Simply Wall St.

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

In late June 2026, Solid Biosciences Inc. was added to several Russell growth indexes, including the Russell 3000 Growth, 2000 Growth, 2500 Growth, and Microcap Growth benchmarks. This broad index inc...

2개월 전 · MT Newswires

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

Sarepta Therapeutics' (SRPT) Elevidys for Duchenne muscular dystrophy shows near-term stabilization,

3개월 전 · Insider Monkey

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged mor...

5개월 전 · TipRanks

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

Solid Biosciences (SLDB) reported updated “positive” interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomark...

5개월 전 · Motley Fool

Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks

Today, March 11, 2026, Oracle’s earnings beat and solid inflation data stand out as U.S. stocks wobble on oil and war fears.

2 페이지 중 1

Solid Biosciences Inc. (SLDB)